{"title":"Association between the biochemical profiles in blood and bone mineral density in Chinese Han population: findings from a cross-sectional study","authors":"Hongxia Chen, Libing Wu, Z. Meng","doi":"10.2147/RRED.S99437","DOIUrl":"https://doi.org/10.2147/RRED.S99437","url":null,"abstract":"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Research and Reports in Endocrine Disorders 2016:6 59–64 Research and Reports in Endocrine Disorders Dovepress","PeriodicalId":90317,"journal":{"name":"Research and reports in endocrine disorders","volume":"6 1","pages":"59-64"},"PeriodicalIF":0.0,"publicationDate":"2016-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/RRED.S99437","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68478078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Crinò, D. Fintini, S. Bocchini, C. Carducci, G. Grugni
{"title":"Prader–Willi syndrome: clinical problems in transition from pediatric to adult care","authors":"A. Crinò, D. Fintini, S. Bocchini, C. Carducci, G. Grugni","doi":"10.2147/RRED.S56401","DOIUrl":"https://doi.org/10.2147/RRED.S56401","url":null,"abstract":"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Research and Reports in Endocrine Disorders 2016:6 49–57 Research and Reports in Endocrine Disorders Dovepress","PeriodicalId":90317,"journal":{"name":"Research and reports in endocrine disorders","volume":"6 1","pages":"49-57"},"PeriodicalIF":0.0,"publicationDate":"2016-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/RRED.S56401","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68477320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Shared decision making and patient choice for growth hormone therapy: current perspectives","authors":"B. George, V. Ayyar","doi":"10.2147/RRED.S79144","DOIUrl":"https://doi.org/10.2147/RRED.S79144","url":null,"abstract":"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Research and Reports in Endocrine Disorders 2016:6 41–48 Research and Reports in Endocrine Disorders Dovepress","PeriodicalId":90317,"journal":{"name":"Research and reports in endocrine disorders","volume":"6 1","pages":"41-48"},"PeriodicalIF":0.0,"publicationDate":"2016-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/RRED.S79144","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68478417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Profile of alglucosidase alfa in the treatment of Pompe disease: safety, efficacy, and patient acceptability","authors":"I. Schneider, S. Zierz","doi":"10.2147/RRED.S72834","DOIUrl":"https://doi.org/10.2147/RRED.S72834","url":null,"abstract":"Pompe disease, also referred to as glycogenosis type II, is a rare, autosomal recessive disorder that results from the deficiency of the glycogen-degrading enzyme acid α- glucosidase. The classical form presents shortly after birth with muscle hypotonia, cardiac, and respiratory failure resulting in a fatal outcome. The late onset of Pompe disease has a very variable onset and disease presentation that often causes a delayed diagnosis. Until now enzyme replacement therapy with alglucosidase alfa is the only causative therapy option for Pompe patients that can slow down disease progression. However, uncertainty remains about the efficacy regarding survival and quality of life in Pompe patients under this very cost-intensive treatment. This paper provides a systematic review of the literature stressing different aspects of enzyme replacement therapy in infantile and late onset Pompe patients.","PeriodicalId":90317,"journal":{"name":"Research and reports in endocrine disorders","volume":"6 1","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2016-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/RRED.S72834","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68477592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Type 1 diabetes: addressing the transition from pediatric to adult-oriented health care.","authors":"Maureen Monaghan, Katherine Baumann","doi":"10.2147/RRED.S56609","DOIUrl":"10.2147/RRED.S56609","url":null,"abstract":"<p><p>Adolescents and young adults with type 1 diabetes are at risk for poor health outcomes, including poor glycemic control, acute and chronic complications, and emergency department admissions. During this developmental period, adolescent and young adult patients also experience significant changes in living situation, education, and/or health care delivery, including transferring from pediatric to adult health care. In recent years, professional and advocacy organizations have proposed expert guidelines to improve the process of preparation for and transition to adult-oriented health care. However, challenges remain and evidence-based practices for preparing youth for adult health care are still emerging. Qualitative research suggests that adolescent and young adult patients rely on health care providers to guide them through the transition process and appreciate a gradual approach to preparing for adult-oriented health care, keeping parents in supportive roles into young adulthood. Patients also benefit from specific referrals and contact information for adult care providers. Promising models of transition care include provision of transition navigators, attendance at a young adult bridge clinic, or joint visits with pediatric and adult care providers. However, much of this research is in its early stages, and more rigorous trials need to be conducted to evaluate health outcomes during transition into adult health care. The purpose of this review is to provide an overview of the transition process, patient and health care provider perceptions of transition care, and emerging evidence of successful models of care for engagement in adult-oriented health care. Recommendations and resources for health care providers are also presented.</p>","PeriodicalId":90317,"journal":{"name":"Research and reports in endocrine disorders","volume":"6 1","pages":"31-40"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68477579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cystic fibrosis-related diabetes: links, challenges, and future directions","authors":"S. Sheikh, A. Kelly","doi":"10.2147/RRED.S68278","DOIUrl":"https://doi.org/10.2147/RRED.S68278","url":null,"abstract":"License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Research and Reports in Endocrine Disorders 2015:5 157–167 Research and Reports in Endocrine Disorders Dovepress","PeriodicalId":90317,"journal":{"name":"Research and reports in endocrine disorders","volume":"5 1","pages":"157-167"},"PeriodicalIF":0.0,"publicationDate":"2015-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/RRED.S68278","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68477701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hsp90 as a therapeutic target in endocrinology: current evidence","authors":"T. Ratajczak, B. Ward, J. Walsh, C. Cluning","doi":"10.2147/RRED.S68546","DOIUrl":"https://doi.org/10.2147/RRED.S68546","url":null,"abstract":"The ability of heat shock protein 90 (Hsp90) to modulate many growth and signal- ing pathways simultaneously makes it an attractive target in the field of cancer therapeutics and provided the initial impetus for significant efforts over the past decade to identify Hsp90 inhibitors, several of which are now showing promise in the clinic for cancer treatment. The four known human Hsp90 members are compartmentalized: Hsp90α and β in the cytoplasm, GRP94 in the endoplasmic reticulum, and TRAP1 in the mitochondrial matrix. While these isoforms share a similar N-terminal domain adenosine triphosphate-binding pocket, structural variations allow unique interactions for inhibitors targeting this binding site, providing an avenue for the development of paralog-selective drugs with different biological effects applicable therapeuti- cally to a wide range of diseases. At the same time, the conformational flexibility of the Hsp90 molecular chaperone has unveiled multiple small-molecule target sites within all subdomains of the protein, greatly expanding opportunities for viable drug development. This review summa- rizes the function, expression, and clinical significance of the Hsp90 isoforms and elaborates on the inhibitors and modulators that impact Hsp90 chaperone activity. Finally, the review focuses on the therapeutic utility of a range of Hsp90-modulating agents in the treatment of specific diseases associated with the endocrine system.","PeriodicalId":90317,"journal":{"name":"Research and reports in endocrine disorders","volume":"5 1","pages":"141-155"},"PeriodicalIF":0.0,"publicationDate":"2015-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/RRED.S68546","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68477519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tatiana Gamboa-Gamboa, Gabriel Abarca-Soto, José G. Jiménez-Montero
{"title":"Prevalence of 25-hydroxyvitamin D deficiency in healthy personnel from an academic institution of an urban area in Costa Rica","authors":"Tatiana Gamboa-Gamboa, Gabriel Abarca-Soto, José G. Jiménez-Montero","doi":"10.2147/RRED.S90435","DOIUrl":"https://doi.org/10.2147/RRED.S90435","url":null,"abstract":"Objective: The aim of this study was to determine 25-hydroxyvitamin D concentrations in healthy employees of the Universidad de Ciencias Médicas, Costa Rica. Methods: Levels of 25-hydroxyvitamin D, calcium, phosphorus, intact parathyroid hormone (iPTH), and creatinine were measured in 80 people. Solar ultraviolet radiation exposure and 25- hydroxyvitamin D intake were estimated using a previously designed questionnaire. Participants were 52 women aged (mean ± standard deviation) 35.8 ± 10.0 years old, body mass index of 27.1 ± 5.9 kg/m 2 , and 26 men aged 36.4 ± 10.8 years old, body mass index of 27.5 ± 5.0 kg/m 2 . Results: All participants were normocalcemic, eight females were postmenopausal, three were hypertensive; none had renal, gastrointestinal, or thyroid disease. The level of 25-hydroxyvitamin D was 23.9 ± 7.0 ng/dL and iPTH 40.1 ± 17.5 pg/dL. A level of 25-hydroxyvitamin D $ 30 ng/dL was seen in 17% of the population. The eight participants with iPTH higher than 67 ng/dL, had 25-hydroxyvitamin D of 18.9 ± 4.8 ng/dL. Two participants who received 25-hydroxyvitamin D and calcium supplements were excluded. Conclusion: The 25-hydroxyvitamin D insufficiency and deficiency found in healthy employees from an academic center in Costa Rica may be due to working long hours in-doors and solar ultraviolet radiation exposure. It is unknown whether secondary hyperparathyroidism seen in nearly 10% of this population, may have long-term effects on bone health.","PeriodicalId":90317,"journal":{"name":"Research and reports in endocrine disorders","volume":"5 1","pages":"135-140"},"PeriodicalIF":0.0,"publicationDate":"2015-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/RRED.S90435","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68478301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}